Topic overview
In brief
- The FDA has allowed certain Zyn nicotine pouches to be marketed as lower risk than cigarettes.
- A study showed a significant increase in nicotine pouch use among 12th graders from 2024 to 2025.
- Experts express concern that increased youth usage could lead to greater health risks and may prompt the FDA to withdraw authorization.
Summary
In the United States, the FDA has authorized certain Zyn nicotine pouches to be marketed as lower risk alternatives to traditional cigarettes. This decision has sparked a debate among public health experts regarding the potential benefits and risks associated with these products. While some experts believe that nicotine pouches can aid current smokers in quitting, there are significant concerns about their appeal to younger audiences, particularly adolescents. The Monitoring the Future study from the University of Michigan reported a rise in lifetime use of nicotine pouches among 12th graders from 6.8% in 2024 to 10.0% in 2025, indicating a growing trend among youth.
Advocates for nicotine pouches argue that they present a safer option compared to combustible tobacco products, which are known to cause severe health issues. Brian Erkkila, a representative from Philip Morris International, shared his personal experience of quitting cigarettes with the help of Zyn, suggesting that these products could have potentially saved his father's life had they been available earlier. However, experts like Bonnie Halpern-Felsher from Stanford University caution that while nicotine pouches may offer harm reduction for adult smokers, the long-term effects on adolescents remain uncertain.